Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691105 · ClinicalTrials.gov registry record · NA
Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 1,044
- Enrollment target
NCT01691105: Completed NA study, sponsored by Yale University.
NCT01691105 is a NA study that has completed, run by Yale University. The registered enrollment target is 1,044 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01691105, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,044 participants
- Enrollment target
Study Summary
This study will implement and test the effectiveness and cost-effectiveness of a tobacco cessation intervention (Academic Detailing + Integrated Tobacco Order Set - AD + ITOS) for adults admitted to the hospital. The intervention will begin during the hospital stay and continue after discharge. The intervention will use resources easily available to most acute care hospitals: computerized physician order entry, physician and nurse education, staff meetings for physicians, nurses and allied health professionals, online learning capabilities, faxing to primary care providers (PCPs), and the telephone counseling and support available from a state smokers' quitline (QL). The investigators hypothesize that the subjects in the intervention arm (AD + ITOS) will be more likely to achieve tobacco abstinence at 12 months post hospital stay than subjects in the control arm (Academic Detailing - AD). Tobacco abstinence will be assessed by self report and biochemical verification (exhaled carbon monoxide reading).
Primary Outcome
Tobacco abstinence will be assessed by obtaining an exhaled carbon monoxide reading for all subjects self-reporting tobacco abstinence at 12 month follow-up. Consistent with manufacturer's recommendations, a cutoff of 10 ppm will indicate current smoking.
Interventions
- OTHER AD + Integrated Tobacco Order Set
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,044 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-09 |
| Phase | NA |
What the finished NCT01691105 record still lists
NCT01691105 is an interventional study that assigns participants to a tested intervention. Its 1,044 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 1 intervention - of which AD + Integrated Tobacco Order Set is the first listed.
NCT01691105 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01691105 about?
NCT01691105 is a clinical study titled "Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers". This study will implement and test the effectiveness and cost-effectiveness of a tobacco cessation intervention (Academic Detailing + Integrated Tobacco Order Set - AD + ITOS) for adults admitted to the hospital. The intervention will begin during the hospital stay and continue after discharge. The ...
What is the current status of trial NCT01691105?
This trial is currently completed. It is a NA study. The enrollment target is 1,044 participants. The study started on 2013-08. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01691105?
The interventions under investigation include: AD + Integrated Tobacco Order Set (OTHER).
Who is sponsoring clinical trial NCT01691105?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01691105's enrollment target sits among peer trials
1,044 100th of 2000 higher than 1,901 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia